Teladoc (TDOC) closed at $6.00, up 1.35% in the latest session, outperforming the S&P 500. However, the stock has declined 8.92% over the past month. The company is expected to report negative EPS of -$0.23 and revenue of $585.55 million, down 6.53% year-over-year. Teladoc holds a Zacks Rank of #3 (Hold), with consensus EPS estimates unchanged over the last 30 days.

Holafly has launched its Ultra Plan, a new international eSIM subscription priced at €84.90/month that combines unlimited mobile data across 160+ destinations with integrated health and wellness services including 24/7 medical messaging, unlimited mental health sessions, nutritional guidance, personal training, and travel assistance. The offering targets frequent travelers, digital nomads, and students, addressing research findings that 47.5% of frequent travelers delay or forgo necessary medical care abroad.

Teladoc Health is expanding its Solo connected care platform with two new AI-powered tools: SoloVitals, which uses smartphone cameras to estimate vital signs during virtual assessments, and SoloScribe, which automates clinical note generation and EHR integration. These additions aim to streamline remote care workflows for hospitals and strengthen Teladoc's position in the competitive virtual healthcare market.

Teladoc (TDOC) declined 3.64% in the latest trading session, significantly underperforming the broader market. The stock has depreciated 7.83% over the past month, underperforming the Medical sector. Upcoming earnings are projected to show a loss of $0.23 per share with revenue declining 6.53% year-over-year. The company holds a Zacks Rank of #3 (Hold) with unchanged consensus EPS estimates over the last 30 days.

The healthcare industry is being overlooked by investors who are primarily focused on artificial intelligence. Healthcare stocks offer relatively stable consumer spending compared to most other industries, presenting potential buying opportunities.

Teladoc stock declined 2.38% to $5.75, underperforming the broader market. The telehealth provider has dropped 7.1% over the past month, significantly worse than the Medical sector's 0.67% loss. Upcoming earnings are projected at -$0.23 per share with quarterly revenue expected at $585.55 million, down 6.53% year-over-year. The stock holds a Zacks Rank of #3 (Hold) with recent analyst estimate revisions showing a 1.62% decrease.

Teladoc (TDOC) fell 3.46% in trading, outpacing the broader market decline. The telehealth services provider faces headwinds with projected EPS of -$0.23 (down 9.52% YoY) and revenue expected at $585.55 million (down 6.53% YoY). The stock holds a Zacks Rank #3 (Hold) rating, with consensus EPS estimates declining 1.78% over the last 30 days.

Teladoc (TDOC) declined 2.33% to $6.28, underperforming the broader market which gained 1.14%. The telehealth services provider faces headwinds with projected EPS of -$0.23 (down 9.52% YoY) and revenue expected at $585.55 million (down 6.53% YoY). The stock holds a Zacks Rank #3 (Hold) rating with EPS estimates revised 1.28% lower over the past 30 days.

The global telepsychiatry market is projected to grow from USD 10.71 billion in 2025 to USD 70.95 billion by 2035 at a CAGR of 20.81%, driven by psychiatrist shortages, reimbursement reforms, and increased adoption of virtual mental healthcare. North America leads with 32% market share, while Asia Pacific shows the fastest growth. Key trends include AI-driven patient matching, employer-sponsored programs, and integration with primary care.

Teladoc Health (TDOC) is positioned for growth through chronic care expansion, international presence, and its upcoming Teladoc One platform, with the stock trading at a valuation discount. However, the company faces headwinds from declining BetterHelp revenues, intense virtual care competition, and persistent unprofitability with a $16.5 billion accumulated deficit.

Pomerantz LLP is investigating potential securities fraud claims against Teladoc Health following the company's significant revenue guidance downgrade on July 29, 2026. Teladoc reduced its full-year 2026 revenue guidance from $2.48-$2.58 billion to $2.36-$2.45 billion, citing uncertainties in cash pay and business model transition. The announcement triggered a 38.32% stock price decline, falling $2.60 per share to $6.58.

The global AI in Patient Engagement Market is projected to grow from USD 7.85 billion in 2025 to USD 45.90 billion by 2035, expanding at a CAGR of 19.34%. Growth is driven by widespread adoption of conversational AI, virtual health assistants, predictive analytics, and remote patient monitoring. North America leads with 38.50% market share, while Asia-Pacific is the fastest-growing region at 23.80% CAGR. Natural Language Processing dominates technology segment with 39.80% share, and cloud deployment accounts for 64.20% of the market.